Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders |
BeiGene, Ltd. (BGNE)
|
Add to portfolio |
|
|
Price: |
$300.31
| | Metrics |
OS: |
1.36
|
B
| |
-46
|
% ROE
|
Market cap: |
$409
|
B
| |
-108
|
% ROIC
|
Net cash:
|
$3.34
|
B
| |
$2.45
|
per share
|
EV:
|
$406
|
B
| | | |
| | | | | |
TTM Valuation | | | |
EBITDA
|
($1.6)
|
B
| |
|
|
EBIT
|
($1.7)
|
B
| |
|
|
EPS |
($1.43)
| |
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
Revenues | 1,415.9 | 1,176.3 | 308.9 | 428.2 | 198.2 | 238.4 | 1.1 | 8.8 |
Revenue growth | 20.4% | 280.8% | -27.9% | 116.0% | -16.8% | 22179.2% | -87.9% | -32.4% |
Cost of goods sold | 286.5 | 164.9 | 70.7 | 71.2 | 28.7 | -5.0 | 0.0 | 0.0 |
Gross profit | 1,129.4 | 1,011.4 | 238.2 | 357.0 | 169.5 | 243.4 | 1.1 | 8.8 |
Gross margin | 79.8% | 86.0% | 77.1% | 83.4% | 85.5% | 102.1% | 100.0% | 100.0% |
Selling, general and administrative | 1,277.9 | 990.1 | 600.2 | 388.2 | 195.4 | 62.6 | 20.1 | 7.3 |
Research and development | 1,640.5 | 1,459.2 | 1,294.9 | 927.3 | 679.0 | 269.0 | 98.0 | 58.3 |
EBITA | -1,642.0 | -1,428.5 | -1,547.3 | -889.6 | -634.9 | -98.2 | -117.1 | -56.7 |
EBITA margin | -116.0% | -121.4% | -501.0% | -207.7% | -320.3% | -41.2% | -10940.2% | -643.7% |
Amortization of intangibles | 4.0 | 1.7 | 0.8 | 1.3 | 0.9 | 0.3 | | |
EBIT | -1,646.0 | -1,430.2 | -1,548.2 | -890.9 | -635.8 | -98.5 | -117.1 | -56.7 |
EBIT margin | -116.2% | -121.6% | -501.2% | -208.0% | -320.7% | -41.3% | -10940.2% | -643.7% |
Pre-tax income | -1,961.0 | -1,438.6 | -1,618.2 | -943.6 | -689.8 | -91.1 | -119.2 | -57.1 |
Income taxes | 42.8 | 19.2 | 10.4 | 7.0 | -15.8 | 2.2 | 0.1 | 0.0 |
Tax rate | | | | | 2.3% | | | 0.0% |
Net income | -2,003.8 | -1,457.8 | -1,625.0 | -948.6 | -673.8 | -93.1 | -119.2 | -57.1 |
Net margin | -141.5% | -123.9% | -526.1% | -221.5% | -339.9% | -39.1% | -11141.8% | -647.7% |
|
Diluted EPS | ($1.49) | ($1.21) | ($1.50) | ($1.22) | ($0.93) | ($0.17) | ($0.30) | ($0.52) |
Shares outstanding (diluted) | 1,340.7 | 1,206.2 | 1,085.1 | 780.7 | 720.8 | 543.2 | 403.6 | 110.6 |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|